Last reviewed · How we verify

NSE dosage "hypothermia arm"

Centre Hospitalier Departemental Vendee · Phase 3 active Biologic

NSE dosage "hypothermia arm" is a Biologic drug developed by Centre Hospitalier Departemental Vendee. It is currently in Phase 3 development for Neuroprotection in acute neurological injury (likely cardiac arrest, stroke, or traumatic brain injury) with therapeutic hypothermia.

NSE dosage in the hypothermia arm likely refers to a neuroprotective strategy using mild hypothermia to reduce neuronal injury during acute neurological events.

NSE dosage in the hypothermia arm likely refers to a neuroprotective strategy using mild hypothermia to reduce neuronal injury during acute neurological events. Used for Neuroprotection in acute neurological injury (likely cardiac arrest, stroke, or traumatic brain injury) with therapeutic hypothermia.

At a glance

Generic nameNSE dosage "hypothermia arm"
SponsorCentre Hospitalier Departemental Vendee
ModalityBiologic
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Therapeutic hypothermia reduces cerebral metabolic rate and inflammation, potentially limiting ischemic or hypoxic brain damage. The 'hypothermia arm' designation suggests this is a comparative study arm testing NSE (neuron-specific enolase) dosing or monitoring in patients undergoing controlled temperature management. NSE itself is a biomarker of neuronal injury rather than a therapeutic agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NSE dosage "hypothermia arm"

What is NSE dosage "hypothermia arm"?

NSE dosage "hypothermia arm" is a Biologic drug developed by Centre Hospitalier Departemental Vendee, indicated for Neuroprotection in acute neurological injury (likely cardiac arrest, stroke, or traumatic brain injury) with therapeutic hypothermia.

How does NSE dosage "hypothermia arm" work?

NSE dosage in the hypothermia arm likely refers to a neuroprotective strategy using mild hypothermia to reduce neuronal injury during acute neurological events.

What is NSE dosage "hypothermia arm" used for?

NSE dosage "hypothermia arm" is indicated for Neuroprotection in acute neurological injury (likely cardiac arrest, stroke, or traumatic brain injury) with therapeutic hypothermia.

Who makes NSE dosage "hypothermia arm"?

NSE dosage "hypothermia arm" is developed by Centre Hospitalier Departemental Vendee (see full Centre Hospitalier Departemental Vendee pipeline at /company/centre-hospitalier-departemental-vendee).

What development phase is NSE dosage "hypothermia arm" in?

NSE dosage "hypothermia arm" is in Phase 3.

What are the side effects of NSE dosage "hypothermia arm"?

Common side effects of NSE dosage "hypothermia arm" include Shivering and discomfort during cooling, Coagulopathy and bleeding risk, Infection risk, Arrhythmias during rewarming.

Related